Loading...
•
Dec 31, 2023
Pulmonx Q4 2023 Earnings Report
Pulmonx reported a record revenue, driven by US growth and strategic execution.
Key Takeaways
Pulmonx Corporation reported a 25% increase in worldwide revenue for Q4 2023, reaching $19.3 million, with significant growth in the U.S. market. The company's gross margin improved to 75%, and it added 14 new Zephyr Valve U.S. treatment centers. They anticipate continued growth and expansion in 2024.
Worldwide revenue increased by 25% to $19.3 million in Q4 2023.
U.S. revenue grew by 45% to $13.7 million in Q4 2023.
Gross margin improved to 75% in Q4 2023.
14 new Zephyr Valve U.S. treatment centers were added in Q4 2023.
Revenue by Geographic Location
Forward Guidance
Pulmonx expects revenue for the full year 2024 to be in the range of $81 million to $84 million. The Company expects gross margin for the full year 2024 to fall within the range of 74% to 75%. Pulmonx expects total operating expenses for the full year 2024 to fall within the range of $132 million to $134 million, inclusive of approximately $30 million of non-cash stock-based compensation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...